Hormonal
GLP-1 receptor agonists provide significant cardiorenal protection, reducing major adverse cardiovascular events (MACE) and kidney-related complications in patients with type 2 diabetes and/or cardiovascular disease, independent of weight loss.
GLP-1 medications do more than help you lose weight; they actively protect your heart and kidneys. For people with diabetes or existing heart/kidney issues, these drugs significantly lower the risk of heart attacks, strokes, and kidney failure. This protection is a key reason why doctors prescribe them, offering benefits beyond just the scale.
Multiple cardiovascular outcomes trials have demonstrated that use of a GLP-1 RA reduces the risk of major adverse cardiovascular events (MACE) among patients with diabetes and at high cardiovascular risk... The FLOW trial demonstrated that, compared to placebo, randomization to semaglutide reduced the risk of kidney-related complications by 24% (HR: 0.76, 95% CI 0.66, 0.88) in patients with diabetes and chronic kidney disease.
Why this rating
Supported by SELECT, FLOW, STEP-HFpEF trials, and observational studies.
Source
The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
Areesha Moiz et al. · EClinicalMedicine · 2025
DOI 10.1016/j.eclinm.2025.103363
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) produce clinically meaningful weight loss of 15–20% in clinical trials, significantly exceeding the modest 3–9% loss from alternative pharmacotherapies and the partial regain seen with lifestyle interventions alone.Strong
- Discontinuation of GLP-1 RA treatment leads to significant weight regain (up to 68% of lost weight) and reversal of cardiometabolic improvements, indicating that obesity requires chronic management.Strong
- GLP-1 receptor agonists are associated with a modestly increased risk of gallbladder and biliary disorders, particularly at higher doses and longer treatment durations.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →